PRTO: Their clinical data to date sure looks like opportunistic highlighting of some endpoints sometimes, and not other times, as well as a dose of good, old-fashioned subgroup analyses. Agree FWIW. (I am sorting through a long list of companies - and hadn't fully digested this one yet.)